Liang Haonan, a specialist infectious diseases, pointed out that the vaccine needs to be based on the strain.Considering that the virus is continuously evolved, the use of Chinese medicine to develop vaccines based on Omikon, which is closest to future variants, is reasonable.
China National Pharmaceutical Group announced on Friday (January 20) that the coronary letter developed by the Chinese creature against Omikon mutant strains enables ribosaccharotic acid (mRNA) vaccine to obtain clinical trial approval by the China Pharmaceutical Supervision Administration.Experts interviewed pointed out that the Chinese medicine has just joined the MRNA R & D army, and there is still a long time before the listing. The German MRNA still has a window period to enter the Chinese market.The time of time or immune escape.
Zhang Yuntao, chief scientist of China Sinopharm Group and vice president of Chinese Biopsy, said that the MRNA vaccine of the middle student Fujian Jianjian Omikon is the innovative MRNA vaccine in China, which is the first long S protein encoding Omikon mutation. It is also China.After the living route of life and reorganization of vaccine, the important milestone results achieved on the MRNA vaccine research and development and production platform.
Zhang Yuntao emphasized that the technical research and development of this MRNA vaccine has been beyond the world's first -class in all aspects.
中 复 诺 <<<<<<<2 billion doses of intelligent vaccine per year
Zhongsheng Fu Nuo Jian has built a trial research and development platform from Shanghai Nanxiang to build a MRNA vaccine drug, and an intelligent MRNA vaccine production workshop with an annual capacity of 2 billion doses.
Liang Haonan, a specialist in infectious diseases in Singapore, explained to Lianhe Zaobao that the vaccine needs to be based on the strain.Considering that the virus is continuously evolved, the use of Chinese medicine to develop vaccines based on Omikon, which is closest to future variants, is reasonable. "The more similar to the strain of future evolution, the more effective it is for future variants."
According to incomplete statistics, there are more than 10 companies in China's layout of MRNA vaccines. With the approval of Chinese medicine, at least eight MRNA vaccines have entered clinical trials. Among themIn the trial production stage, the design capacity is 100 million doses, which will also be one of the first vaccines developed by China using MRNA technology.
Local public health experts who did not speak to the media because they were not authorized to speak to the media told Lianhe Zaobao that the research and development cycle of traditional vaccines spans decades. From the current situation, the MRNA vaccine research and development, including national medicine, including national medicine,Chinese manufacturers have been listed one year to several years.However, she also said that the German MRNA vaccine Fubitai only took less than eight months from clinical declaration to emergency authorization.
The German government has been in contact with the Chinese government since the end of November last year.The Ministry of Health of Germany also released the import of Chinese Kochi vaccine in early December, which was interpreted by German media as a process of promoting Fu Bitai's approval in China.However, as of now, China has not yet approved its own people to vaccinate imported coronary vaccines in China.
Wang Yubo, an associate professor at the School of Economics and Management of the University of Hong Kong, was judged in an interview with Lianhe Morning Post that China ’s large -scale imported mRNA vaccine is unlikely.Regardless of the support of the ethnic industry in biopharmaceuticals or for the face of a large country, considering the stage of the epidemic in China, "the possibility of reaching an agreement with the international biopharmaceutical giant in the next few months is relatively low."
The aforementioned unknown public health experts believe that the current popular Omikon's immune escape is significant, and large -scale natural infections cannot completely replace vaccines. Vaccination is still the key to crown disease prevention. Foreign MRNA vaccines still have a chanceEnter Chinese market.
